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ABSTRACT Long-term noninvasive ventilation (NIV) to treat chronic hypercapnic respiratory failure is
still controversial in severe chronic obstructive pulmonary disease (COPD) patients. However, with the
introduction of high-intensity NIV, important benefits from this therapy have also been shown in COPD.
In this review, the focus will be on the arguments for long-term NIV at home in patients with COPD. The
rise of (high-intensity) NIV in COPD and the randomised controlled trials showing positive effects with
this mode of ventilation will be discussed. Finally, the challenges that might be encountered (both in
clinical practice and in research) in further optimising this therapy, monitoring and following patients, and
selecting the patients who might benefit most will be reviewed.
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Chronic obstructive pulmonary disease (COPD) is a disease with high mortality and morbidity worldwide [1].
Patients with end-stage COPD frequently develop chronic hypercapnic respiratory failure (CHRF)
associated with end-of-life. In this stage of disease, patients experience extremely disabling symptoms of
dyspnoea, leading to severely impaired health-related quality of life (HRQoL), with limited treatment
options.
Long-term nocturnal noninvasive ventilation (NIV) has been applied in patients with chronic alveolar
hypoventilation for decades. While there is no doubt that applying chronic nocturnal NIV improves
outcomes in patients with restrictive and neuromuscular diseases [2–4], there has been conflicting
evidence for its benefits in COPD patients for a long period [5–15]. This has led to enormous variety in
the application of long-term NIV in COPD throughout Europe [16]. However, with the introduction of
high-intensity NIV (HI-NIV), important benefits have been shown [17–20] and the discussion about NIV
in COPD has changed. Nevertheless, despite these positive findings, the application of long-term NIV in
patients with severe COPD should be considered carefully, as knowledge gaps remain with regard to
patient selection, the optimal place to initiate NIV and the optimal ventilatory settings to be used.
In this review, the focus will be on the arguments for long-term NIV at home in patients with COPD. The
evolution of (high-intensity) NIV in COPD and the randomised controlled trials (RCTs) showing positive
effects with this mode of ventilation will be discussed. Furthermore, the challenges that might be
encountered (both in clinical practice and in research) in further optimising this therapy and selecting the
patients who benefit most will be reviewed.
The history of high-intensity noninvasive ventilation
The first reports of NIV in stable severe COPD date from the 1980s. During this period, negative pressure
ventilation using a cuirass or poncho warp ventilator was the most widely used ventilatory mode. These
first studies on negative pressure ventilation in stable severe COPD showed variable results, with some
smaller trials showing a positive effect on gas exchange, respiratory muscle strength, hospitalisation rates,
or dyspnoea [21–26] and some, including a large RCT, showing no benefit at all [27, 28]. Furthermore,
almost all studies concluded that there was poor patient tolerance for long-term use of negative pressure
ventilation [28].
In the mid-1980s, positive pressure ventilation became more widely available. It was expected that this
mode would improve tolerance and outcomes. However, in contrast to the situation in neuromuscular or
restrictive thoracic diseases, in which positive pressure ventilation gained more and more popularity, the
benefits of this more easily tolerable mode of ventilation were still not demonstrated unambiguously in
COPD. Although the first positive pressure ventilation trials were small [12] or uncontrolled, trials
including more patients and a randomised design also did not show any (or only very limited) benefits in
gas exchange, lung function, symptoms or HRQoL [5, 6, 8, 9, 11–13].
Randomised controlled trials using high-intensity noninvasive ventilation
More than 15 years ago, the concept of HI-NIV was introduced by WINDISCH et al. [18]. Considering the
studies performed prior to that time [5, 6, 8, 9, 12, 13] they concluded that most used inadequate
ventilatory settings with which no effect on ventilation and gas exchange could have been expected in
severe COPD patients. One of the first reports pinpointing this problem was that by MEECHAM JONES et al. [10],
in which they showed that with a moderate inspiratory airway pressure (IPAP) of 18 cmH2O, nocturnal
gas exchange improved. This improvement in nocturnal gas exchange correlated with daytime
improvements in gas exchange and so it was hypothesised that to achieve any benefit in gas exchange and
other patient centred outcomes, one first had to be sure that effective ventilation was achieved.
The Windisch group started to ventilate their COPD patients with high inspiratory pressures and a high
back-up respiratory rate (BURR). They first reported on their outcomes in a retrospective cohort [18, 19]
and, although these data were uncontrolled and retrospective and there was surely a patient selection bias,
the amount of improvement in gas exchange, lung function and HRQoL was impressive. To confirm those
results, they set-up a randomised cross-over trial in which they showed that HI-NIV improved gas
exchange and HRQoL as compared to the previously used “low-intensity” NIV settings [17]. However, the
settings used in these studies were extremely high when compared to previous and a lot of caregivers
were concerned about compliance with them. Although the Windisch group started to redefine HI-NIV as
“…The concept of using higher IPAP levels in addition to controlled ventilation aiming for maximal PaCO2
reduction…” [29] and showed that compliance and sleep quality were not worse with HI-NIV and could
even be better when compared to low-intensity NIV (LI-NIV) [30, 31], in real life it remained difficult to
achieve the HI-NIV goals in all patients. Patient tolerance with this setting often limits the range in which
IPAP and BURR can be increased.
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Unfortunately, we lack knowledge about what HI-NIV is actually doing with the respiratory system and
why it is sometimes difficult to get patients to adjust to it (patients certainly need more time to get used
to HI-NIV, leading to more hospitalisation days [17, 32]). Furthermore, while the concept of HI-NIV
seemed to be rather effective, parallel-group RCTs were needed which showed the feasibility and clinical
benefits of this mode in real-life situations. Until now, three larger randomised controlled studies [33–35]
have been published that show important benefits of HI-NIV in severe COPD. Of particular note is the
fact that these studies were performed under different circumstances. Moreover, the negative RESCUE trial
shows no effect of HI-NIV in a cohort of patients that continued HI-NIV after an exacerbation [36].
Figure 1 illustrates the development of ventilatory settings over time and the studies in which these
settings are used. The RCTs using HI-NIV and the RESCUE trial will be discussed extensively in the
following sections.
Noninvasive ventilation as an addition to pulmonary rehabilitation in severe stable COPD
Pulmonary rehabilitation is a well proven effective treatment to improve HRQoL, relieve dyspnoea, reduce
exacerbations and improve self-management in patients with symptomatic COPD of any stage [1]. It is
also effective in patients with severe COPD but might be problematic to fulfil as patients experience
disabling symptoms of dyspnoea and lowering of energy levels. In 2011, the results of the RECOVER trial
were published where it was investigated whether, in stable severe COPD, the addition of NIV to a
multidisciplinary pulmonary rehabilitation programme would improve outcomes as compared to
pulmonary rehabilitation alone [33, 37]. In this study, a ventilatory strategy was used in which the aim was
to achieve normocapnia during daytime by increasing IPAP and BURR. Eventually, after a quite intensive
investment in optimal NIV titration (mean hospitalisation 7 days, including 2 arterial blood gas recordings
in the intensive care unit), patients were ventilated with a mean IPAP of 24 cm H2O and a BURR of
18 breaths·min−1. Only three out of 31 patients randomised to the NIV+pulmonary rehabilitation group
dropped out because of intolerance to the therapy. With this strategy we showed that, in patients with
moderate CHRF (mean arterial carbon dioxide tension (PaCO2) at baseline 6.8 kPa), adding NIV improved
HRQoL and dyspnoea, and, of particular note, stabilised or even improved forced expiratory volume in 1 s
(FEV1) over the complete study period of 2 years (figure 2). In fact, patients on NIV were far better
equipped to maintain the improvement they achieved during the first 12-week inpatient rehabilitation
programme during the 21 months of outpatient rehabilitation afterwards.
Noninvasive ventilation as an addition to standard care in severe stable COPD
KÖHNLEIN et al. [34] showed in a large RCT that treating COPD patients suffering from severe CHRF with
NIV impressively improves survival. 195 patients with very severe CHRF in stable condition were
randomised either for addition of NIV to their standard therapy (in all patients this included long-term

























































































































FIGURE 1 Evolution of ventilatory settings in randomised controlled trials investigating noninvasive ventilation
in stable or post-exacerbation chronic obstructive pulmonary disease. IPAP: inspiratory airway pressure;
EPAP: expiratory airway pressure; BURR: back-up respiratory rate.
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36 hospitals throughout Germany and Austria and these hospitals were instructed to ventilate with a
high-intensity approach, aiming at a reduction in daytime PaCO2 of at least 20%. To achieve this, patients
were hospitalised for a mean of 5.6 days. Eventually, patients ended up with a mean IPAP of 21.6 cmH2O
and a mean BURR of 16 breaths·min−1. Adding NIV to standard care improved survival from 77% in the
standard care group to 88% in the NIV+standard care group. Of note, it seems that this survival benefit
was achieved immediately after initiation of NIV, a period in which patients with this degree of CHRF
(mean PaCO2 7.8 kPa at baseline) are probably extremely vulnerable. Furthermore, besides benefits in gas
exchange, FEV1, exercise tolerance and HRQoL were also improved.
Noninvasive ventilation after severe exacerbations
Patients who become respiratory insufficient due to a COPD exacerbation and need invasive or
noninvasive mechanical ventilation for the acute event have a very poor prognosis after hospital discharge
[38–42]. More than 60% of these patients are readmitted and more than 25% die within the first year after
discharge [39]. Therefore, the thought that continuation of NIV at home after discharge might be helpful
is quite attractive. MURPHY et al. [35] recently showed that when you initiate NIV in patients that remain
severely hypercapnic after an exacerbation, hospital readmissions are delayed and reduced. This study was
also an important landmark in the NIV field, as this important benefit was achieved not only through
adequate ventilatory settings (mean IPAP 24 cmH2O, mean BURR 14 breaths·min
−1) but also through
very careful patient selection (only patients that had still a daytime PaCO2 >7.5 kPa 2–4 weeks after
discharge from the index hospital admission were included). However, it might be possible that a
substantial proportion of chronic hypercapnic patients were included that were already hypercapnic before
the index hospital admission, a group for which it was already known that NIV was of benefit. In
addition, patients that were unable to tolerate NIV during the index hospital admission were excluded.
This patient selection might explain the differential result as compared to the RESCUE trial by STRUIK
et al. [36]. In the latter, 201 patients were included that were moderately hypercapnic 48 h after weaning
from NIV or invasive mechanical ventilation and randomised to NIV or standard care to be continued for
a year. This study did not show any benefit at all despite the use of HI-NIV (mean IPAP 19 cmH2O, mean
BURR 5 breaths·min−1), probably because many patients in the control group showed spontaneous
recovery in their PaCO2.
Noninvasive ventilation in COPD
Four larger well-designed RCTs have been performed using HI-NIV in patients with severe COPD [33, 34,
36, 43]. In stable chronic hypercapnic patients, two studies showed quite convincing benefits although a
survival benefit was only shown in one study (level B evidence) [33, 34]. In patients in whom NIV was
initiated, or in whom it was continued after an exacerbation with acute respiratory failure, evidence is
mixed; however, is seems that when you select patients that remain hypercapnic, important benefits with
regard to rehospitalisation can be achieved (level B evidence) [43]. Nevertheless, from these studies it
becomes clear that challenges have to be overcome with regard to patient selection, the timing of NIV and
the optimal (HI)-NIV settings to be used.
Challenges in noninvasive ventilation
Patient selection and outcomes
NIV is most convincingly of benefit in COPD patients with CHRF in a stable condition [33, 34]. Patients
with very severe hypercapnia seem to benefit more, at least with respect to gas exchange benefits (this
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FIGURE 2 Forced expiratory volume in 1 s (FEV1) results in the RECOVER trial. FEV1 was measured at
different points for the noninvasive intermittent positive pressure ventilation (NIPPV) + rehabilitation group
(red triangles) and the rehabilitation group (blue squares). The change was significantly better in the NIPPV +
rehabilitation group (p<0.02). Reproduced from [33] with permission from the publisher.
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most important outcome parameter remains an interesting discussion. In fact, patients usually care most
about their quality of life (QoL), might care about survival (with good QoL), but usually do not care about
PaCO2 changes. Furthermore, although some studies have shown that hypercapnia is associated with a
worse prognosis [44–46], it is unclear whether NIV-induced changes in PaCO2 influence HRQoL or
survival. BUDWEISER et al. [46] showed that patients with a base excess of >9 mmol·L−1 might improve their
survival once this is lowered by NIV; however, such a base excess of 9 mmol·L−1 represents an extreme
CHRF state, much worse than that in the Köhnlein trial. For patients with moderate CHRF this
relationship has not been shown; moreover, for HRQoL there seems to be no relationship with PaCO2. This
means that the positive effects of NIV reach beyond solely an improvement in gas exchange and, maybe,
that improvements in HRQoL might themselves improve survival [47]. Important HRQoL benefits have
also been shown in moderate hypercapnic patients [33, 37]. It has been hypothesised that NIV facilitates a
more active way of living and therefore a better ability of patients to work on their general life style.
Indeed, it has been shown that positive effects can be obtained when you combine NIV with pulmonary
rehabilitation [33]. In severely hypercapnic COPD patients, studies show only small benefits in HRQoL,
probably because HRQoL is influenced by many other factors, such as a poor general condition or
comorbidities, which tend to be more prevalent in patients with more severe COPD.
In patients that exacerbate frequently the benefits of NIV are less certain. Despite MURPHY et al. [35]
showing that NIV might increase the time to readmission and rehospitalisation, effects on HRQoL were
disappointing. In this study, only patients that remained severely hypercapnic (who were probably already
chronically hypercapnic before the index exacerbation) were included and these patients probably benefit
in terms of readmission risk. It should be noted, however, that the reduction of hospitalisation rates does
not apply for patients that recover faster, as has been shown by STRUIK et al. [11]. Also, it is unclear which
group of patients benefit from a reduction in readmissions and exacerbations and at the same time an
improved HRQoL.
Optimal settings to be applied
HI-NIV, defined as “…the concept of using higher IPAP levels than used in most of the older RCTs in
addition to controlled ventilation aiming for maximal PaCO2 reduction…” [29], is the preferential mode of
ventilation in COPD. Benefits have been shown with this mode; however, this definition is quite vague and
positive and potential negative effects of HI-NIV have only been investigated in limited fashion. Furthermore,
in clinical practice, increasing IPAP and BURR might lead to patient discomfort. Increasing our knowledge
about the mechanisms of HI-NIV and how we should adjust our settings most adequately to act upon
potential negative factors will improve ventilatory efficacy, patient tolerance and eventually outcomes.
Understanding the mechanisms involved
As per the definition above, HI-NIV improves arterial blood gases and this improved gas exchange has
positive effects on certain symptoms, such as morning headache. Nevertheless it is unknown by which
mechanisms 1) arterial blood gases are improved and 2) other (patient-centered) outcomes, such as
HRQoL and survival, are improved. Why HI-NIV works remains a “black box” and the relationship
between an improvement in gas exchange and other outcomes is not as clear as it may seem.
WINDISCH et al. [20] showed in one of their first studies that HI-NIV is able to improve breathing patterns.
This improved breathing pattern, with higher tidal volumes, lower breathing frequencies and higher
minute ventilation, can be maintained during the day, possibly as a consequence of a change in respiratory
drive or improved pulmonary mechanics because of a decrease in hyperinflation. The hypothesis that NIV
improves respiratory drive has only been investigated in two small trials, as follows: 1) ELLIOT et al. [48]
showed that the change in PaCO2 in 12 stable COPD patients correlated with the increase in ventilation
during a rebreathing manoeuvre (at an end-tidal CO2 value of 8 kPa), and 2) NICKOL et al. [49] showed
findings of improved chemosensitivity as a reason for improved ventilation and thus gas exchange.
While this might be an attractive explanation for patients that show depressed respiratory drive, COPD
patients with a small breathing reserve and a high respiratory drive, who are breathing close to the fatigue
threshold, might need additional mechanisms in order to enable them to increase their ventilation in
response to a certain level of increased PaCO2. In this respect it is attractive to search for changes in lung
function, i.e. airway obstruction and/or hyperinflation, as a way to unload the heavily loaded respiratory
system in COPD. That NIV is able to decrease hyperinflation was shown by DIAZ et al. [50], who showed
impressive improvements in residual volume and intrinsic positive end-expiratory pressure with short
periods of daytime NIV. Also, the mechanistic studies of Elliot and Nickol showed effects on
hyperinflation parameters. Unfortunately, lung volumes were seldom investigated in longer-term nocturnal
studies.
https://doi.org/10.1183/23120541.00012-2018 5
COPD | M.L. DUIVERMAN
An interesting finding in the high-intensity trials is that NIV seems to be able to stabilise FEV1 [17, 19, 33, 34],
meaning that NIV directly affects airway characteristics. First, it might be that NIV, as it dilates airways at
least a couple of hours during the day, opposes bronchoconstriction-induced effects on the airways. It is
known that mechanical forces occurring in the airway as a consequence of bronchoconstriction are
sufficient to not just induce symptoms but also to influence airway biology [51–53]. On the other hand, it
is known that therapies such as mechanical ventilation and prevention of vagally-induced airway narrowing
by targeted lung denervation have positive effects on airways [54]. Furthermore, patients with chronic
hypercapnia are known to retain fluid because the renin–angiotensin–aldosterone system (RAAS) is
activated. This excess fluid might be retained in the airway wall and, if hypercapnia is reduced, oedema
might decrease and airway dilation might occur. However, it is completely unknown how NIV acts on
airway characteristics, as these studies are quite complex to perform in patients with severe COPD.
Interestingly, complex studies have shown that airflow redistribution into the lungs may change on NIV,
thereby improving ventilation-perfusion matching [55, 56].
A long-standing hypothesis is that NIV rests overloaded fatigued respiratory muscles [57]. In fact, it is
questionable as to whether the respiratory muscles are fatigued, as several reports support the hypothesis
that chronic hypercapnic COPD patients adopt a pattern of rapid shallow breathing to prevent the muscles
becoming fatigued [58–60]. This would mean that patients act as “wise fighters”, not pushing their
probably weaker [61] muscles to the limits. Furthermore, it is known that the diaphragm of these patients
adapts to the chronic overload by developing more fatigue resistant Type I fibres [62]. Also, studies of NIV
do not provide us with much evidence that the respiratory muscles are rested [63]. Notably, the methods
by which this phenomenon was assessed were differential and it should be noted that maximal inspiratory
pressure measurements in particular do not reflect muscle fatigue adequately [64]. Nevertheless, while the
diaphragm might not be fatigued, it is known that all kinds of cellular and molecular alterations occur that
reduce the force generating capacity of diaphragm muscle fibers [61, 62]. Therefore, it might still be
possible that respiratory muscle rest or recovery contribute to the improved balance between capacity/drive
and respiratory system load, leading to improved breathing patterns and gas exchange.
Finally, in addition to these direct effects augmenting (alveolar) ventilation, chronic NIV has a beneficial
effect on other factors that improve respiratory symptoms and HRQoL (figure 3). However, it is not
correct to conclude that the improvement in gas exchange is responsible for all of the clinically relevant
improvements achieved, as the relationship between gas exchange parameters and HRQoL for example is
very limited. Effects such as improvement in sleep quality and sputum clearance, and a reduction in
exacerbation rate probably all act positively on HRQoL [40, 65, 66].
Potential negative factors
There has been an extensive discussion about patient comfort with HI-NIV and many caregivers feel they
should lower settings once patients experience discomfort. Despite this, studies have shown that compliance
was better with effective high-intensity settings as compared to ineffective low-intensity settings [17], while







FIGURE 3 The influence of noninvasive ventilation (NIV) on the delicate balance between increased load and
decreased capacity of the respiratory system in severe chronic obstructive pulmonary disease (COPD). The
radiography image is reproduced from Radiology Assistant (www.radiologyassistant.nl) with permission.
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sleep quality was not worse with HI-NIV [30]. Even the volume-assured settings promoted for comfort did
not provide better comfort and tolerance, nor did they provide physiological benefits [67–70]. On the other
hand, the time patients need to get used to the high-intensity setting is increased as compared to the “old”
low-intensity setting [17, 32]. Improvements in our capability to monitor patients adequately might
improve the initiation process, for example by monitoring of patients work of breathing, respiratory events
and patient–ventilator asynchrony. For hospital care this might lead to a significant shortening of the
hospital stay for NIV initiation and might also help us to initiate patients remotely at home.
A substantial proportion of COPD patients have cardiac comorbidities and we should be aware of the
potentially negative effects of HI-NIV on the heart in such cases. The effects of mechanical ventilation on
cardiac function are diverse and might result in both positive and negative clinical outcomes [71]. It is
known that HI-NIV might reduce cardiac output [72] and, in a small purely physiological study,
LUKACSOVITS et al. [73] showed that a setting with a mean IPAP of 28 cmH2O decreased left ventricular
output. However, this study used quite extreme settings and investigated effects only after a short period of
NIV, while clinical relevance was not investigated. It has also been shown [32] that if patients use their
NIV for a longer period of time, on average, no change in cardiac output or clinical cardiac outcomes
(such as N-terminal pro-brain natriuretic peptide (NT-proBNP)) occurs. However, both of these studies
were small and this field is surely of interest for future research.
Some caregivers are worried that with HI-NIV the diaphragm is insufficiently unloaded and that
diaphragm atrophy will result. It has been shown that even with very high-intensity HI-NIV, with a
breathing frequency above the patients’ own, patients still trigger the ventilator substantially [74].
Furthermore, patients use their ventilator intermittently, so that periods of spontaneous breathing with
high diaphragm loading remain. Also, studies that tested respiratory muscle strength did not show a
deterioration that might be an indication of diaphragm atrophy [37].
Another issue that requires attention is that in clinical practice a substantial proportion of COPD patients
on HI-NIV experience deventilation dyspnoea, a feeling of severe dyspnoea after being disconnected from
the ventilator. This phenomenon has been investigated only in a limited fashion and questions remain as
to whether this is a consequence of a forced change in breathing patterns after switching off from the
ventilator, the respiratory muscles taking over from a situation of almost controlled ventilation, or a
substantial extra degree of hyperinflation induced by a too limited expiratory time for the volume inhaled
(especially when the BURR is high) [75]. One small study has shown that if you adjust ventilator settings
on polysomnographic titration, in this case leading mainly to a decrease in IPAP, deventilation dyspnoea
also decreases [76]. However, it is still not known which mechanisms cause the dyspnoea and exactly
which changes occur when you adjust ventilator settings in such a dedicated way.
Initiation of high-intensity noninvasive ventilation
Initiating and following patients on chronic NIV at home may be a very attractive option both for patients
and the healthcare system. Rapidly evolving techniques of telemedicine assist in the transfer of more care
from the hospital to the home. However, while these techniques provide us with extensive capabilities to
monitor patients, studies on the follow-up of chronic hypercapnic patients on home NIV have given
ambiguous results with respect to a reduction in exacerbations and rehospitalisations, as well as to HRQoL
[77–79]. Several aspects, such as the content of the telemedicine intervention (what are important data to
measure and collect, and how are the results managed etc), the set-up of the healthcare service (how do
healthcare professionals act upon results) and geographical differences can influence the effects that
telemedicine can provide [80]. Too much monitoring without a thorough self-management plan might
cause over reliance on healthcare professionals and an increase in healthcare utilisation instead of a
decrease [77]. This emphasises the need for a proper selection of the setting for telemedicine: do you want
to transfer in-hospital care to “at least as good” home care, or add care to the standard which should, in
that case, improve outcomes? Initiation of home NIV, which is now regularly done during a hospital
admission, is an example of care that might be transferred to the home situation. In two well-designed
RCTs, it was shown that home initiation of NIV is as good as in-hospital initiation in patients with
neuromuscular disease or restrictive thoracic disorders [81, 82]. In COPD, some of the old RCTs initiated
their patients at home [12] but they used LI-NIV and home monitoring, and guidance was very limited or
not available. When we initiate patients on HI-NIV, careful monitoring is a must have. Fortunately,
technology is evolving and allows us to use remote monitoring for an almost unlimited number of
parameters (such as transcutaneous gas exchange measures, ventilator data and patient–ventilator
asynchrony), to save data on online platforms or view it on a real-time basis, and to use these data to
assist us in decision making and the remote adjustment of ventilator settings. Although the handling of
these extensive data provides us with new challenges, for the initiation period their integration might be
very helpful and provide clues to success.
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Conclusions
Several good quality RCTs have shown that if adequate ventilatory settings are applied, aimed at a
substantial reduction in PaCO2, then chronic NIV improves outcomes in patients with severe CHRF. An
impressive survival benefit was shown; however, outcomes can be further improved once we increase our
knowledge about which patients will potentially benefit and how exactly NIV works on the respiratory and
non-respiratory system. In this way we are able to adjust our settings based on mechanism, individual
patient characteristics and the presence of comorbidities. Although this seems rather complex, the goal
should be to develop a treatment algorithm which can easily guide treatment and could as well be applied
at home. If the expectation is that the number of COPD patients with an indication for chronic NIV will
continue to rise and that patients’ preferences are usually for care in the home setting, then home
initiation and monitoring of chronic NIV will be the future.
Lessons for clinicians
Duiverman has helpfully clarified what we have learnt about long-term noninvasive ventilation (NIV) in
chronic obstructive pulmonary disease (COPD) over the last few decades. The take home points are:
• NIV achieves benefits in COPD patients with persistent hypercapnia.
• Control of arterial carbon dioxide tension (PaCO2) is a key target and high-intensity NIV is an effective
way to achieve this.
• NIV is a cost effective therapy, as early results from the HOT-HMV study [35] suggest only five
chronically hypercapnic COPD patients need to be treated with NIV to avoid one death.
However, organisational effort will be required to follow-up with patients who are hypercapnic 2 weeks or
more after an acute exacerbation and institute therapy. In addition, we need to know more on several
fronts:
• If quality of life (QoL) is improved (and here results are mixed)-for how long?
• How does home NIV affect the very end-stage of COPD?
• Symptom palliation with NIV can be valuable but should NIV be withdrawn at the end-of-life: what
are our patients’ views on this?
Long-term NIV in COPD is a story to be continued!
Anita K. Simonds, Chief Editor
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